Table 1. Patient demographics and... | American Society of Hematology

Table 1.

Patient demographics and treatments

Patient no.	Age, y	Sex	Stage	No. prior systemic therapies	Bexarotene dose, mg/d	No. cycles denileukin diftitox administered
1	67	F	IIA	3	75	12
2	46	F	IVB	1	150	4
3	55	M	IIB	2	150	7
4	70	M	III	2	150	9
5	46	M	IVA	1	150	6
6	57	M	IA	1	150	9
7	72	F	III	6	225	4
8	63	F	IB	1	225	7
9	71	M	III	11	225	1
10	64	F	IIA	5	300	3
11	60	M	IB	2	300	5
12	81	F	IB	2	300	4
13	56	F	IB	1	375	4
14	61	F	IVB	1	225	4

Patient no.	Age, y	Sex	Stage	No. prior systemic therapies	Bexarotene dose, mg/d	No. cycles denileukin diftitox administered
1	67	F	IIA	3	75	12
2	46	F	IVB	1	150	4
3	55	M	IIB	2	150	7
4	70	M	III	2	150	9
5	46	M	IVA	1	150	6
6	57	M	IA	1	150	9
7	72	F	III	6	225	4
8	63	F	IB	1	225	7
9	71	M	III	11	225	1
10	64	F	IIA	5	300	3
11	60	M	IB	2	300	5
12	81	F	IB	2	300	4
13	56	F	IB	1	375	4
14	61	F	IVB	1	225	4